USFDA issues 7 observations to Dr. Reddy's biologics facility in Hyderabad

Regulatory & Legal View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹1349.50

prior close

₹1388.40

announcement price

After-mkt

timing

Nifty 100market-0.5%+2.8% vs market

Pharmaceuticals peers, median of 165sector+0.1%+2.2% vs sector

On the reaction day the stock moved 2.8 pts more than Nifty 100 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.2

15m

+0.6

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3-0.5+2.8+0.1+2.2

Next day

+0.7-0.8+1.5+0.9-0.2

-0.8-0.2-0.6+0.4-1.2

-0.4+0.5-0.9+0.9-1.3

+1.6+0.7+0.9+1.8-0.2

+1.1+1.4-0.3+1.6-0.5

+0.1-0.9+1.0+0.1-0.0

15d

-9.5+0.7-10.2+1.8-11.3

-15.3+0.8-16.1+1.6-16.9

-14.5+0.5-14.9+1.3-15.8

-7.2-5.2-2.0+4.8-12.1

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The USFDA completed a Pre-License Inspection at Dr. Reddy's biologics manufacturing facility in Bachupally, Hyderabad, from June 16 to June 25, 2026. The company received a Form 483 with seven observations, which it plans to address within the stipulated timeline. This follows earlier inspections disclosed in October 2023 and September 2025.

Likely market impact

Form 483 observations may delay approvals from this facility. Addressable, no warning letter yet; near-term biologics pipeline impact possible.